Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Cadence Pharmaceuticals
With that in mind, let's take a closer look at Cadence's business and see what CAPS investors are saying about the stock right now.
Cadence facts
| Headquarters (Founded) | San Diego (2004) |
| Market Cap | $267.2 million |
| Industry | Pharmaceuticals |
| Trailing-12-Month Revenue | $10.8 million |
| Management | Co-Founder/CEO Theodore Schroeder CFO William LaRue |
| Return on Capital (Average, Past 3 Years) | (44.9%) |
| Cash/Debt | $67.6 million / $27.2 million |
| Competitors |
Cephalon Cumberland Pharmaceuticals Pacira Pharmaceuticals |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 33% of the 102 members who have rated Cadence believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star zzlangerhans, tapped the stock as an untimely opportunity:
I expect Cadence will display a pattern of weakly increasing revenues that never match the increasing cost of sales and SGA expenses. The share price has remained relatively stable since the last PR, but I expect the stock will gap down again when the next quarterly earnings statement comes out in early March.
What do you think about Cadence, or any other stock for that matter? If you want to retire rich, you need to protect your portfolio from any undue risk. Staying away from dangerous stocks is crucial to securing your financial future, and on Motley Fool CAPS, thousands of investors are working every day to flag them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
